Tuesday, February 12, 2019 - 07:00
  • Appointments of Dr. Mondher Mahjoubi, Chief Executive Officer, and Dr. Yannis Morel, EVP Business Development and Portfolio Strategy, renewed to the Executive Board for three years

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the Supervisory Board of Innate Pharma has strengthened the Company’s leadership and corporate governance with the appointment of Laure-Hélène Mercier, Chief Financial Officer, as a member of the Executive Board for a period of three years.

Laure-Hélène Mercier, MSc, MBA, has served as the Executive Vice President and Chief Financial Officer since late 2016 and has a 10-year tenure at Innate Pharma. 

The Supervisory Board has also renewed the appointments to the Executive Board of Dr. Mondher Mahjoubi, CEO, and Dr. Yannis Morel, EVP Business Development and Portfolio Strategy, for three additional years.

As from January 31, 2019, the Executive Board is now composed of three members, appointed for a three-year period.

 

AttachmentSize
PR in English 110.05 KB
CP en français 99.54 KB